RT Journal Article
SR Electronic
T1 An Informatics Consult approach for generating clinical evidence for treatment decisions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.10.21249331
DO 10.1101/2021.01.10.21249331
A1 Alvina G. Lai
A1 Wai Hoong Chang
A1 Constantinos A. Parisinos
A1 Michail Katsoulis
A1 Ruth M. Blackburn
A1 Anoop D. Shah
A1 Vincent Nguyen
A1 Spiros Denaxas
A1 George Davey Smith
A1 Tom R. Gaunt
A1 Krishnarajah Nirantharakumar
A1 Murray P. Cox
A1 Donall Forde
A1 Folkert Asselbergs
A1 Steve Harris
A1 Sylvia Richardson
A1 Reecha Sofat
A1 Richard J.B. Dobson
A1 Aroon Hingorani
A1 Riyaz Patel
A1 Jonathan Sterne
A1 Amitava Banerjee
A1 Alastair K. Denniston
A1 Simon Ball
A1 Neil J. Sebire
A1 Nigam H. Shah
A1 Graham R. Foster
A1 Bryan Williams
A1 Harry Hemingway
YR 2021
UL http://medrxiv.org/content/early/2021/01/15/2021.01.10.21249331.abstract
AB An Informatics Consult has been proposed in which clinicians request novel evidence from large scale health data resources, tailored to the treatment of a specific patient, with return of results in clinical timescales. However, the availability of such consultations is lacking. We seek to provide an Informatics Consult for a situation where a treatment indication and contraindication coexist in the same patient, i.e., anti-coagulation use for stroke prevention in a patient with both atrial fibrillation (AF) and liver cirrhosis. We examined four sources of evidence for the effect of warfarin on stroke risk (efficacy) or all-cause mortality (safety) from: (i) randomised controlled trials (RCTs), (ii) meta- analysis of prior observational studies, (iii) trial emulation (using population electronic health records (N = 3,854,710) and (iv) genetic evidence (Mendelian randomisation). We developed prototype forms to request an Informatics Consult and return of results in electronic health record systems. We found 0 RCT reports and 0 trials recruiting for patients with AF and cirrhosis. We found broad concordance across the three new sources of evidence we generated. Meta-analysis of prior observational studies showed that warfarin use was associated with lower stroke risk (hazard ratio [HR] = 0.71). In a target trial emulation, warfarin was associated with lower all-cause mortality (HR = 0.61) and ischaemic stroke (HR = 0.27). Mendelian randomisation served as a drug target validation where we found that lower levels of vitamin K1 (warfarin is a vitamin K1 antagonist) are associated with lower stroke risk. A pilot survey with an independent sample of 34 clinicians revealed that 85% of clinicians found information on prognosis useful and that 79% thought that they should have access to the Informatics Consult as a service within their healthcare systems. We identified candidate steps for automation to scale evidence generation and to accelerate the return of results within clinical timescales.Competing Interest StatementAB has received research funding from AstraZeneca for work unrelated to this research. GRF receives funding from companies that manufacture drugs for hepatitis C virus (AbbVie, Gilead, MSD) and consults for GSK, Arbutus and Shionogi in areas unrelated to this research. TRG and GDS have received research funding from GlaxoSmithKline and Biogen for work unrelated to this research.Funding StatementAGL is supported by funding from the Wellcome Trust (204841/Z/16/Z), National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (BRC714/HI/RW/101440), NIHR Great Ormond Street Hospital Biomedical Research Centre (19RX02) and the Health Data Research UK Better Care Catalyst Award (CFC0125). MK is funded by the British Heart Foundation (FS/18/5/33319). RMB is supported by a UKRI Innovation Fellowship funded by the Medical Research Council (Grant No: MR/S003797/1). ADS is supported by a postdoctoral fellowship from THIS Institute. RJBD is supported by the NIHR Biomedical Research Centres at South London and Maudsley NHS Foundation Trust (SLAM; IS-BRC1215-20018); Health Data Research UK; UK Research and Innovation (UKRI) London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare; the BigData@Heart Consortium (Grant No. 116074 of the European Union Horizon 2020 programme); the NIHR BRC and Research Informatics Unit at University College London Hospitals; and the NIHR Applied Research Collaboration South London at KCHFT. GDS and TG are funded by the Medical Research Council Integrative Epidemiology Unit at the University of Bristol MC_UU_00011/1&4. HH is an NIHR Senior Investigator and is funded by the NIHR University College London Hospitals Biomedical Research Centre, supported by Health Data Research UK (LOND1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medicines Healthcare Regulatory Authority (UK) Independent Scientific Advisory Committee (reference: 20_078R). Ethics approval has been received.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is shown in the manuscript.